FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Matthew Voss

Research Profile

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Percy H Carter; Robert J Cherney; Gregory D Brown; Sarah R King; Yvonne C Lo; Sandhya Mandlekar; Persymphonie B Miller; Peggy A Scherle; Andrew J Tebben; Matthew E Voss; Gengjie Yang; Qihong Zhao; Carl P Decicco
Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.
Robert J Cherney; Ruowei Mo; Dayton T Meyer; Matthew E Voss; Michael G Yang; Joseph B Santella; John V Duncia; Yvonne C Lo; Gengjie Yang; Persymphonie B Miller; Peggy A Scherle; Qihong Zhao; Sandhya Mandlekar; Mary Ellen Cvijic; Joel C Barrish; Carl P Decicco; Percy H Carter
gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
Carlton L Campbell; Carla Hassler; Soo S Ko; Matthew E Voss; Michael A Guaciaro; Percy H Carter; Robert J Cherney
Enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxymethyl)cyclohexylcarbamate using an iodolactamization as the key step.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Matthew Voss (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Percy H Carter; Robert J Cherney; Gregory D Brown; Sarah R King; Yvonne C Lo; Sandhya Mandlekar; Persymphonie B Miller; Peggy A Scherle; Andrew J Tebben; Matthew E Voss; Gengjie Yang; Qihong Zhao; Carl P Decicco
Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.
Bioorganic & medicinal chemistry letters 2012;22(9):3311-6.
2010: Robert J Cherney; Ruowei Mo; Dayton T Meyer; Matthew E Voss; Michael G Yang; Joseph B Santella; John V Duncia; Yvonne C Lo; Gengjie Yang; Persymphonie B Miller; Peggy A Scherle; Qihong Zhao; Sandhya Mandlekar; Mary Ellen Cvijic; Joel C Barrish; Carl P Decicco; Percy H Carter
gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
Bioorganic & medicinal chemistry letters 2010;20(8):2425-30.
2009: Carlton L Campbell; Carla Hassler; Soo S Ko; Matthew E Voss; Michael A Guaciaro; Percy H Carter; Robert J Cherney
Enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxymethyl)cyclohexylcarbamate using an iodolactamization as the key step.
The Journal of organic chemistry 2009;74(16):6368-70.
2009: Robert J Cherney; Ruowei Mo; Dayton T Meyer; Matthew E Voss; Yvonne C Lo; Gengjie Yang; Persymphonie B Miller; Peggy A Scherle; Andrew J Tebben; Percy H Carter; Carl P Decicco
Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
Bioorganic & medicinal chemistry letters 2009;19(13):3418-22.
2003: Robert J Cherney; James J-W Duan; Matthew E Voss; Lihua Chen; Li Wang; Dayton T Meyer; Zelda R Wasserman; Karl D Hardman; Rui-Qin Liu; Maryanne B Covington; Mingxin Qian; Sandhya Mandlekar; David D Christ; James M Trzaskos; Robert C Newton; Ronald L Magolda; Ruth R Wexler; Carl P Decicco
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Journal of medicinal chemistry 2003;46(10):1811-23.
2003: Zelda R Wasserman; James J-W Duan; Matthew E Voss; Chu-Biao Xue; Robert J Cherney; David J Nelson; Karl D Hardman; Carl P Decicco
Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling.
Chemistry & biology 2003;10(3):215-23.
2003: Matthew E Voss; Percy H Carter; Andrew J Tebben; Peggy A Scherle; Gregory D Brown; Lorin A Thompson; Meizhong Xu; Yvonne C Lo; Gengjie Yang; Rui-Qin Liu; Paul Strzemienski; J Gerry Everlof; James M Trzaskos; Carl P Decicco
Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-alpha antagonists.
Bioorganic & medicinal chemistry letters 2003;13(3):533-8.
2001: Percy H Carter; Peggy A Scherle; J K Muckelbauer; Matthew E Voss; Rui-Qin Liu; Lorin A Thompson; Andrew J Tebben; Kimberly A Solomon; Yvonne C Lo; Z Li; P Strzemienski; Gengjie Yang; N Falahatpisheh; M Xu; Z Wu; N A Farrow; Kalyanaraman Ramnarayan; J Wang; D Rideout; V Yalamoori; Peter J Domaille; D J Underwood; James M Trzaskos; Steven M Friedman; Robert C Newton; Carl P Decicco; J A Muckelbauer
Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(21):11879-84.
2001: Chu-Biao Xue; Matthew E Voss; David J Nelson; James J-W Duan; Robert J Cherney; Irina C Jacobson; Xiaohua He; John Roderick; Lihua Chen; Ronald L Corbett; Li Wang; Dayton T Meyer; K Kennedy; W F DeGradodagger; Karl D Hardman; Christopher A Teleha; BD Jaffee; Rui-Qin Liu; Robert Copeland; Maryanne B Covington; David D Christ; James M Trzaskos; Robert C Newton; Ronald L Magolda; Ruth R Wexler; Carl P Decicco
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
Journal of medicinal chemistry 2001;44(16):2636-60.